AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04028570 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Varying Doses of Background and Boost RT
Description: 3+3 radiation dose escalation model to see the maximum tolerated dose for background and boost radiation therapy.
Study NCT02514434 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
Study NCT02514434 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: non-contrast MRI
Description: Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
Study NCT04092491 — intervention group
Intervention type: OTHER
Intervention: blood sample
Description: 1 blood sample during a consultation carried out as part of a medical follow-up:~* 2 PAXgene RNA tubes of 2 ml each~* 1 dry tube for creatinine and IgA assay~* 1 tube of NFs (5ml)
Study NCT03602846 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Medical Nutrition Therapy
Description: Only given medical nutrition therapy.
Study NCT03602846 — intervention group
Intervention type: DRUG
Intervention: Insulin
Description: Prescribed with rapid acting, intermediate acting, mixed or long acting insulin.
Study NCT03602846 — intervention group
Intervention type: DRUG
Intervention: Oral Antidiabetics
Description: Prescribed with all types of oral anti-diabetics.
Study NCT03511391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab or Pembrolizumab or Atezolizumab
Description: per national standard of care
Study NCT03511391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab or Pembrolizumab or Atezolizumab
Description: per national standard of care
Study NCT03511391 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic body radiotherapy is administered to maximally 3 lesions in 3 fractions of 8Gy prior to the second/third cycle of checkpoint inhibitors.
Study NCT01687777 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stem Cells (MSCs)
Description: 20.000.000 autologous MSCs included in the OrthADAPT membrane. Single dosage.
Study NCT01687777 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: OrthADAPT
Study NCT01790139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral simethicone
Description: 10 mL of simethicone is administered as an agent to prevent colonic bubbles
Study NCT02226575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives
Description: Controls only delivery standard care. Experimental group deliver standard care plus a distress management program (cognitive behavioral therapy) performed in groups by a nurse, a pedagogue and a cardiologist (all trained in the distress management program).
Study NCT04151316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: crown preparation
Description: includes tooth preparation
Study NCT01670929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Study NCT01670929 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04151316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vertical preparation
Description: type of vertical preparation on the tooth that accepts the crown
Study NCT04151316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: horizontal preparation
Description: type of horizontal preparation on the tooth that accepts the crown
Study NCT05044910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Ready to Use supplementary food (RUSF)
Description: Children with malnutrition will be given RUSF
Study NCT05046275 — intervention group
Intervention type: OTHER
Intervention: Data analysis
Description: No intervention, data analysis only
Study NCT00354172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: 10 Million units subcutaneous every other day on days -13 (after Natural killer cell graft), -11, -9, -7, -5, -3) If \< 45 kilograms (Kg) - interleukin (IL)-2 at 5 MU/m2
Study NCT00354172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: All patients will receive filgrastim (same as granulocyte-colony stimulating factor or G-CSF) 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight beginning on day +1 after umbilical cord blood (UCB) infusion. Granulocyte Colony Stimulating Factor (G-CSF) will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10\^9/L for three consecutive days and then discontinued. If the ANC decreases to \<1.0 x 10\^9/L, G-CSF will be reinstituted.
Study NCT00312936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction (MBSR)
Description: 8 week program
Study NCT02435875 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: Antihypertensive drug as intervention is used to see if it can improve baroreflex sensitivity to stable perioperative hemodynamic
Study NCT02073591 — intervention group
Intervention type: OTHER
Intervention: Ceradan Cream
Study NCT02073591 — intervention group
Intervention type: OTHER
Intervention: Ceradan Wash
Study NCT02452775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OC-L
Study NCT02452775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Montanide
Study NCT02452775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: poly-ICLC (Hiltonol),
Study NCT00354172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: natural killer cell (NK) therapy
Description: All CD3 depleted cells will be given (less those required for product monitoring). The minimum size of a starting NK cell unit will be 700 million mononuclear cells before processing. NK cells (CD56+) and NK cell precursors (CD34+/CD7-, CD34+/CD7+, CD34-/CD7+) will be monitored and reported but will not serve as lot release.
Study NCT00354172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide to be administered with high volume fluid flush and mesna on days-18 and -17 after fludarabine. Cyclophosphamide 60 mg/kg/day intravenously (IV) x 2 days, total dose 120 mg/m2 (days -18 and -17)
Study NCT00354172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Patients will receive cyclosporine (CSA) therapy beginning on day -1 maintaining a level of >200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children \<40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
Study NCT00354172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -18 to -16)
Study NCT03677609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindset & Communication Training
Description: The mindset training is a two-hour, live training, with a one-hour follow-up one month later, that teaches care providers to recognize, shape, and leverage patient mindsets in healthcare.
Study NCT03303547 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI mapping to guide pathological sampling of extranodal tumour deposits
Description: Radiologist to mark areas where extranodal disease is identified on MRI. The pathologist will use this to take additional samples for analysis. This will allow better pathological staging and will affect treatment decisions for patients.
Study NCT04607889 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Interviews with study participants will be conducted by telephone or teleconference. The interview will focus on the participants experience with genomic tests, with the expectations, reasons for taking or declining it, hurdles encountered, satisfaction among the key themes to be discussed.
Study NCT03588091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: pyrotinib: 400mg orally daily;
Study NCT03588091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo: 400mg orally daily;
Study NCT01801306 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NeMo Probe
Description: A new minimal-invasive brain tissue probe applying near infrared spectroscopy
Study NCT01477775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral P2Y12 receptor blocker
Description: Free choice among clopidogrel, prasugrel or ticagrelor
Study NCT01477775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Customized choice for the oral P2Y12 receptor blocker
Description: one drug among clopidogrel, prasugrel or ticagrelor based on an algorithm integrating phenotype information.
Study NCT03353415 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dexcom CGM masked
Description: The CGM will monitor sensor glucose levels in all participants. (Initially the Dexcom G4 was worn by participants (n=13); however, when the G4 became unavailable, the G6 was worn by the subsequent participants (n=10)).~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation).
Study NCT03353415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom CGM unmasked
Description: During the second phase (2 weeks for the Dexcom G4 and 10 days for the Dexcom G6), participants are able to see the sensor glucose levels displayed from the CGM. Participants will be instructed to use this information to treat low glucose levels before symptoms or severely low glucose levels develop.~The duration of the Dexcom G4 sensor was 7 days (2 sensors placed during each phase of participation) versus the Dexcom G6 whose sensor duration is 10 days (1 sensor placed during each phase of participation).
Study NCT03632837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemoadsorption
Description: see arm description
Study NCT02546180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Viewing YouTube videos
Description: The on-line patient education program will highlight postoperative care.
Study NCT02546180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard preoperative education
Description: Standard preoperative education will be provided by the surgeon, physician extender and paramedical staff in the clinic.
Study NCT01013402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human insulin
Description: The test was performed in the morning after an overnight fasting and the patients remained supine during the procedure. Two intravenous lines in both arms were established before the procedure. Venous blood was obtained for serum glucose before regular insulin (0.1 U/kg ) is injected and 30 and 45 minutes thereafter. If adequate hypoglycemia was not achieved at this period, a second dose of regular insulin (0.05U/kg) was injected intravenously. In subjects who had not reached the aimed hypoglycemia levels, the test was performed in another day with a higher initial insulin dosage (0.2U/kg).
Study NCT01013402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin
Description: 0.1U/kg IV pulse.
Study NCT00308230 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Six minute walk test
Study NCT02517697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14 Nitrogen (N) Sodium Nitrite
Description: oral formulation of sodium nitrite 40 mg three times daily for 12 weeks
Study NCT00308230 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Six minute walk test
Study NCT00308230 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minnesota Living with Heart Failure Questionnaire
Study NCT00308230 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Minnesota Living with Heart Failure Questionnaire
Study NCT03588091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 4 cycles;
Study NCT03588091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trastuzumab
Description: trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 4 cycles;
Study NCT02269800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride solution
Description: Tid, 7 days
Study NCT02269800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Tid, 7 days
Study NCT03588091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel:after the biological window, 100mg/m2 for a total of 4 cycles
Study NCT03588091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: docetaxel:after the biological window, 100mg/m2 for a total of 4 cycles
Study NCT00856882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy protein
Study NCT00856882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: isoflavones
Study NCT00856882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: milk protein
Study NCT00856882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: milk protein
Study NCT04753008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine administration
Description: Administration of dopamine (3 mcg/kg/min) as part of cardiac support therapy after the cardiopulmonary bypass. Administration of dopamine is a subject of clinical decision based on the cardiovascular status of the patients.
Study NCT04707573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: oral capsules
Study NCT00446693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoFast Reliant™ system for Pelvic Organ Prolapse repair
Description: The EndoFast Reliant™ system is a new concept of reinforcing the vaginal wall with proprietary mesh and soft-tissue Fasteners in a minimally-invasive procedure.
Study NCT00682786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Study NCT00682786 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Study NCT00682786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery of resectable lesions
Study NCT00682786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT02082015 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low frequency rTMS
Description: Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: tangential to scalp
Study NCT02082015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency rTMS
Description: Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: tangential to scalp
Study NCT02438423 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated influenza vaccine
Description: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season
Study NCT02438423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Description: Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season
Study NCT02517697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral formulation of matching placebo three times daily for 12 weeks
Study NCT00187252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Atrial Overdrive Pacing
Description: Pacemaker/ ICD implant
Study NCT00561600 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ASR™-XL Modular Acetabular Cup System
Description: The ASR™-XL Modular Acetabular Cup System treatment device is comprised of a metal acetabular cup, a unipolar femoral head and a taper sleeve adapter.
Study NCT00561600 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pinnacle™ acetabular shell
Description: The Pinnacle™ shells are cementless, titanium alloy cups with Porocoat® porous coating and HA DuoFix™ coating. There are various different liners available for use with the Pinnacle™ Acetabular Cup System. For the purpose of this investigation, the CoCrMo ULTAMET® 28mm or 36 mm metal liners will be used.
Study NCT00187252 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial Overdrive Pacing
Description: Pacemaker/ ICD implant
Study NCT04886713 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Adipose and myocardial tissue sampling
Description: After median sternotomy tissue samples will be collected from the epicardial space, the abdominal wall and the myocardium.
Study NCT04886713 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac magnetic resonance imaging
Description: Magnetic resonance imaging will be performed at 1.5 Tesla ('Intera', Philips Medical Systems, Best, The Netherlands). All subjects will be examined in the supine position with initial anatomy scans to cover the thorax to the first sacral vertebrae. The magnetic resonance imaging protocol is summarized in Figure 4.~The following imaging parameters will be acquired:~* Biventricular end-diastolic and end-systolic volume, ejection fraction, stroke volume~* Biventricular mass, wall thickness~* T1 mapping; native and > 10 minutes post contrast injection as an estimate of left ventricular diffuse fibrosis and extracellular volume~* Late enhancement for detection of regional fibrosis and scar~* Myocardial feature tracking for analysis of deformation/motion~* Epicardial fat volume
Study NCT04886713 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise testing
Description: After completion of a regular cardiac rehabilitation program patients are scheduled to undergo their discharge examination at 3 to 4 weeks after the operation in order to be functionally characterized. Cardiopulmonary exercise testing will be performed, if possible by patients condition, on a mechanically braked bicycle ergometer and respiratory gas exchange analysis via a mouthpiece or facemask.
Study NCT01928927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Participants received Telmisartan 40 mg daily during weeks 0-4 followed by telmisartan 80 mg daily during weeks 5-48.
Study NCT02631980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV iron
Description: Intravenous iron 15 mg/kg (max 1000 mg) in 250 ml 0.9% saline
Study NCT02631980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV placebo
Description: Intravenous 0.9% saline (250 ml)
Study NCT03415204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture for post operative pain
Study NCT01522326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 400mg tablet. Take one dose by mouth.
Study NCT01522326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Metoclopramide 10mg tablet. Take one tablet by mouth.
Study NCT03609996 — intervention group
Intervention type: DEVICE
Intervention: Panretinal Photocoagulation
Description: Laser treatment for PDR
Study NCT03609996 — intervention group
Intervention type: DRUG
Intervention: Lucentis
Description: Intraviteral injection
Study NCT03027622 — intervention group
Intervention type: BEHAVIORAL
Intervention: quality of life in the patients with mild pericoronitis
Description: active surviallence by OHIP-14 TR after treatment
Study NCT02936635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirasemtiv
Description: Oral
Study NCT00741975 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Management
Description: 12-session group intervention including affect management training as well as sexual health skills training
Study NCT00741975 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Promotion
Description: 12-session group intervention including health information on a variety of developmentally relevant health topics
Study NCT01504152 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: The intervention is a self-administered questionnaire that is voluntarily completed by the subject. This questionnaire has been previously validated and demonstrated to be reproducible in English speaking travelers. The final version of the survey questionnaire consists of 49 questions.Patients who never traveled after HSCT will answer only eighteen questions related to their medical and HSCT history in addition to their demographics.
Study NCT02815540 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 12-Lead ECG
Description: Subjects will be monitored while on cannabidiol with a 12-Lead ECG and/or Holter monitoring
Study NCT01929226 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETI-204
Description: Monoclonal Antibody
Study NCT02815540 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cannabidiol
Description: Subjects who are planning to take state dispensed medical cannabidiol, or are already taking state dispensed medical cannabidiol.
Study NCT04259307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omapone Peri 724mL or Winuf Peri 654mL
Description: Additional intravenous nutrition of 500 kcal per day for 3 weeks